Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Amortization of Deferred Charges: 2019-2024

Historic Amortization of Deferred Charges for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Dec 2024 value amounting to $2.9 million.

  • Maravai Lifesciences Holdings' Amortization of Deferred Charges fell 47.08% to $399,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 35.96%. This contributed to the annual value of $2.9 million for FY2024, which is 1.13% down from last year.
  • Per Maravai Lifesciences Holdings' latest filing, its Amortization of Deferred Charges stood at $2.9 million for FY2024, which was down 1.13% from $2.9 million recorded in FY2023.
  • In the past 5 years, Maravai Lifesciences Holdings' Amortization of Deferred Charges registered a high of $19.0 million during FY2020, and its lowest value of $2.7 million during FY2021.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $2.9 million (2024), whereas its average is $2.9 million.
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Amortization of Deferred Charges soared by 995.85% in 2020, and later slumped by 85.92% in 2021.
  • Yearly analysis of 5 years shows Maravai Lifesciences Holdings' Amortization of Deferred Charges stood at $19.0 million in 2020, then crashed by 85.92% to $2.7 million in 2021, then rose by 4.19% to $2.8 million in 2022, then climbed by 5.06% to $2.9 million in 2023, then declined by 1.13% to $2.9 million in 2024.